The estimated Net Worth of Chris Francis is at least $3.55 Million dollars as of 16 February 2023. Christopher Francis owns over 10,258 units of Wave Life Sciences stock worth over $470,313 and over the last 8 years he sold WVE stock worth over $1,394,951. In addition, he makes $1,682,290 as Senior Vice President - Corporate Development and Head of Emerging Areas at Wave Life Sciences.
Sign up
Christopher Francis WVE stock SEC Form 4 insiders trading
Christopher has made over 10 trades of the Wave Life Sciences stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 10,258 units of WVE stock worth $41,340 on 16 February 2023.
The largest trade he's ever made was exercising 48,992 units of Wave Life Sciences stock on 30 May 2018 worth over $121,500. On average, Christopher trades about 8,059 units every 101 days since 2016. As of 16 February 2023 he still owns at least 79,714 units of Wave Life Sciences stock.
You can see the complete history of Christopher Francis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Francis biography
Dr. Christopher John Francis Ph.D. serves as Senior Vice President - Corporate Development, Head of Emerging Areas of the Company. serves as Senior Vice President - Corporate Development, Head of Emerging Areas of the Company. During the period January 2017 to May 2017, Dr. Francis served as our Senior Vice President, Corporate Development & Portfolio Management. Prior to that, Dr. Francis served as our Vice President, Head of Business Development since April 2014. Prior to joining us, Dr. Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology from 2009 to 2014 and was a member of the team that established GlaxoSmithKline’s Rare Disease Unit. Before GlaxoSmithKline, Dr. Francis was a health care private equity associate at Two River LLC from 2008 to 2009. He began his career in pharmaceutical pricing and reimbursement consulting at IMS Health. Dr. Francis earned undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge.
What is the salary of Christopher Francis?
As the Senior Vice President - Corporate Development and Head of Emerging Areas of Wave Life Sciences, the total compensation of Christopher Francis at Wave Life Sciences is $1,682,290. There are 1 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.
How old is Christopher Francis?
Christopher Francis is 42, he's been the Senior Vice President - Corporate Development and Head of Emerging Areas of Wave Life Sciences since 2017. There are 17 older and 1 younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.
What's Christopher Francis's mailing address?
Chris's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE, MA, 02138.
Insiders trading at Wave Life Sciences
Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ..., and Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.
What does Wave Life Sciences do?
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
What does Wave Life Sciences's logo look like?
Complete history of Christopher Francis stock trades at Wave Life Sciences
Wave Life Sciences executives and stock owners
Wave Life Sciences executives and other stock owners filed with the SEC include:
-
Paul Bolno,
President, Chief Executive Officer, Director -
Christopher Francis,
Senior Vice President - Corporate Development, Head of Emerging Areas -
Michael Panzara,
Chief Medical Officer -
Chandra Vargeese,
Senior Vice President, Head of Drug Discovery -
Dr. Paul B. Bolno M.B.A., M.D., MBA,
Pres, CEO & Director -
Dr. Michael A. Panzara M.D., M.P.H., MPH,
Chief Medical Officer and Head of Therapeutics Discovery & Devel. -
Dr. Chandra Vargeese Ph.D.,
Chief Technology Officer -
Gregory Verdine,
Director -
Mark Corrigan,
Independent Director -
Amy Pott,
Independent Director -
Heidi Wagner,
Independent Director -
Christian Henry,
Independent Chairman of the Board -
Peter Kolchinsky,
Independent Director -
Ken Takanashi,
Independent Director -
Adrian Rawcliffe,
Independent Director -
Koji Miura,
Independent Director -
Kenneth Rhodes,
Senior Vice President - Therapeutics Discovery -
David Gaiero,
Interim Chief Financial Officer -
Kate Rausch,
Investor Relations -
Anne-Marie Li-Kwai-Cheung,
Sr. VP of Regulatory Affairs, Compliance & Policy -
Dr. Sridhar Vaddeboina Ph.D.,
Sr. VP of Chemistry, Manufacturing & Controls -
Jose Juves,
Sr. VP of Corp. Affairs & Patient Advocacy -
Jonathan Rosin,
Chief HR Officer -
Dr. Christopher Francis Ph.D.,
Sr. VP of Corp. Devel. & Head of Emerging Areas -
Linda Rockett J.D.,
Gen. Counsel -
Kyle B. Moran CFA,
CFO & Principal Accounting Officer -
Chris Francis,
See Remarks -
Plc Gsk,
10% owner -
Keith Regnante,
Chief Financial Officer -
Takeshi Wada,
Director -
Ken Shin Nippon Biomedical ...,
-
Masaharu Kagoshima Shinsang...,
-
Roberto Guerciolini,
See Remarks -
Masaharu Tanaka,
Director -
Peter Kolchinsky,
Director -
Capital Management, Llc Kol...,
-
Mark Baldry,
Chief Commerical Officer -
Capital Management, L.P.Ra ...,
-
Kyle Moran,
Chief Financial Officer -
Aik Na Tan,